BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35027560)

  • 1. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
    Nachmanson D; Officer A; Mori H; Gordon J; Evans MF; Steward J; Yao H; O'Keefe T; Hasteh F; Stein GS; Jepsen K; Weaver DL; Hirst GL; Sprague BL; Esserman LJ; Borowsky AD; Stein JL; Harismendy O
    NPJ Breast Cancer; 2022 Jan; 8(1):6. PubMed ID: 35027560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
    Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
    Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
    Murphy DS; Hoare SF; Going JJ; Mallon EE; George WD; Kaye SB; Brown R; Black DM; Keith WN
    J Natl Cancer Inst; 1995 Nov; 87(22):1694-704. PubMed ID: 7473818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
    Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T
    Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology.
    McCart Reed AE; Kutasovic JR; Nones K; Saunus JM; Da Silva L; Newell F; Kazakoff S; Melville L; Jayanthan J; Vargas AC; Reid LE; Beesley J; Chen XQ; Patch AM; Clouston D; Porter A; Evans E; Pearson JV; Chenevix-Trench G; Cummings MC; Waddell N; Lakhani SR; Simpson PT
    J Pathol; 2018 Apr; 244(4):460-468. PubMed ID: 29344954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ductal Carcinoma In Situ - Quo Vadis?
    Peltecu G
    Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ductal carcinoma in situ of the breast: histological classification and genetic alterations.
    van de Vijver MJ
    Recent Results Cancer Res; 1998; 152():123-34. PubMed ID: 9928552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lobular Carcinomas
    Lee JY; Schizas M; Geyer FC; Selenica P; Piscuoglio S; Sakr RA; Ng CKY; Carniello JVS; Towers R; Giri DD; de Andrade VP; Papanastasiou AD; Viale A; Harris RS; Solit DB; Weigelt B; Reis-Filho JS; King TA
    Clin Cancer Res; 2019 Jan; 25(2):674-686. PubMed ID: 30185420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast.
    Fujii H; Szumel R; Marsh C; Zhou W; Gabrielson E
    Cancer Res; 1996 Nov; 56(22):5260-5. PubMed ID: 8912866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.
    Rane SU; Mirza H; Grigoriadis A; Pinder SE
    Breast Cancer Res Treat; 2015 Aug; 153(1):101-21. PubMed ID: 26255059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
    Nachmanson D; Steward J; Yao H; Officer A; Jeong E; O'Keefe TJ; Hasteh F; Jepsen K; Hirst GL; Esserman LJ; Borowsky AD; Harismendy O
    BMC Med Genomics; 2020 Nov; 13(1):173. PubMed ID: 33208147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Huang CY; Chang RF; Lin CY; Hsieh MS; Liao PC; Wang YJ; Kao YC; Porta L; Lin PY; Lee CC; Lee YH
    Histopathology; 2024 May; 84(6):983-1002. PubMed ID: 38288642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Escape in Breast Cancer During
    Gil Del Alcazar CR; Huh SJ; Ekram MB; Trinh A; Liu LL; Beca F; Zi X; Kwak M; Bergholtz H; Su Y; Ding L; Russnes HG; Richardson AL; Babski K; Min Hui Kim E; McDonnell CH; Wagner J; Rowberry R; Freeman GJ; Dillon D; Sorlie T; Coussens LM; Garber JE; Fan R; Bobolis K; Allred DC; Jeong J; Park SY; Michor F; Polyak K
    Cancer Discov; 2017 Oct; 7(10):1098-1115. PubMed ID: 28652380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.
    Johnson KC; Koestler DC; Fleischer T; Chen P; Jenson EG; Marotti JD; Onega T; Kristensen VN; Christensen BC
    Clin Epigenetics; 2015; 7(1):75. PubMed ID: 26213588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic clonal mapping of in situ and invasive ductal carcinoma indicates the field cancerization phenomenon in the breast.
    Foschini MP; Morandi L; Leonardi E; Flamminio F; Ishikawa Y; Masetti R; Eusebi V
    Hum Pathol; 2013 Jul; 44(7):1310-9. PubMed ID: 23337025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.